Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Diagn Microbiol Infect Dis ; 103(3): 115715, 2022 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-35598409

RESUMEN

Chlamydia (C.) abortus is an emerging zoonotic pathogen. Since data on its antimicrobial susceptibility are lacking, we aimed to determine minimal inhibitory (MIC) and minimal bactericidal concentrations (MBC) for azithromycin and doxycycline in HeLa-cells and primary human macrophages (M1). We also examined the MDM2-p53-inhibitor nutlin-3, an anti-infective imidazoline analog. Azithromycin and doxycycline demonstrated MICs and MBCs equal or below their peak serum concentrations (PSC) after standard dosing in both cell types. While doxycycline exhibited an MIC 64-fold and an MBC 4-fold below its PSC in HeLa-cells, the MIC of azithromycin was 4-fold below, the MBC equal to the PSC. However, azithromycin revealed lower MBCs in M1. The pharmacological advantage of azithromycin accumulation in phagocytes and their role as chlamydial reservoirs remain uncertain. However, our data suggest possible therapeutic advantages of doxycycline in epithelial cells and we provide first evidence for an anti-C. abortus effect of nutlin-3 in M1.


Asunto(s)
Antibacterianos , Infecciones por Chlamydia , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Azitromicina/farmacología , Chlamydia , Chlamydia trachomatis , Doxiciclina/farmacología , Doxiciclina/uso terapéutico , Células Epiteliales , Humanos , Imidazoles , Macrófagos , Piperazinas , Proteínas Proto-Oncogénicas c-mdm2/farmacología , Proteína p53 Supresora de Tumor/farmacología , Proteína p53 Supresora de Tumor/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA